Related Experiment Video
Updated: Mar 8, 2026
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Evolution of Nerve Conduction Demyelinating Parameters Between Baseline and Treatment Cessation May Not Be Predictive
Marine Le Vavasseur1, Capucine Blaise1, Isabelle Cordelle2
1Service de Physiologie Clinique-Explorations Fonctionnelles, APHP, DMU DREAM, Hôpital Lariboisière, Paris, France.
Introduction/Aims:
Identifying factors associated with short-term relapse is essential for tailoring maintenance treatment on a case-by-case basis in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We sought to determine whether changes in demyelinating electrophysiological features during treatment could predict relapse after treatment discontinuation in a cohort of CIDP patients.
Methods:
We conducted a retrospective study of patients with CIDP treated with intravenous immunoglobulin (IVIg), all of whom had a first nerve conduction study (NCS) at treatment initiation or during treatment, while the disease was in a stable phase, followed by a second study at the time of treatment discontinuation. Demyelinating features and the degree of axonal loss were determined during each NCS and compared between the two examinations.
Results:
Thirty-one consecutive IVIg-responsive CIDP patients were included, with a mean age of 59.1 ± 14.6 years. Twenty (65%) were males. Sixteen patients (52%) relapsed after a mean of 6 months. Most patients demonstrated a reduced total number and type of demyelinating features between the two assessments, but overall, these changes were not different between the relapse and relapse-free groups. Similarly, axonal loss at our first assessment and the progression of axonal loss between our two assessments were not different in the relapse group compared to the relapse-free group.
Discussion:
In our population of IVIg responsive CIDP patients, we were unable to demonstrate the predictive value of follow-up nerve conduction studies alone for the risk of relapse. Looking at other biomarkers alone or in combination with NCS is necessary.
